Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRVg-2 Immunogenicity and Safety in Healthy Adults
NCT03145766Phase 2Completed
- Sponsor
- Sanofi
- Start
- Apr 2017
- Primary completion
- Jan 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of rabies vaccine serum-free vero cell in rabies (5 arms), sponsored by Sanofi. Primary endpoints: Rabies Virus Neutralizing Antibody Geometric Mean Titers at Month 7, Percentage of Participants With Rabies Virus Neutralizing Antibody Titer >= 0.5 IU/mL at Month 7 and 3 more. Started Apr 2017; status: completed.
02
Drugs
rabies vaccine serum-free vero cell
03
Conditions
rabies
Beyond the preview
Go deeper on NCT03145766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03145766.